Gilead Announces Partnership With PEPFAR to Deliver Twice-Yearly Lenacapavir for HIV Prevention for up to Two Million People in Primarily Low- and Lower-Middle-Income Countries - Candlesense
GILD Partnership

Gilead Announces Partnership With PEPFAR to Deliver Twice-Yearly Lenacapavir for HIV Prevention for up to Two Million People in Primarily Low- and Lower-Middle-Income Countries

(NASDAQ:GILD) FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced a partnership with the U.S. State Department and the United States President’s Emergency Plan for AIDS Relief (PEPFAR) to deliver lenacapavir—Gilead's twice-yearly injectable HIV-1 capsid inhibitor—for the prevention of HIV as pre-exposure prophylaxis (PrEP). This is a key component of Gilead’s larger coordinated efforts, now bringing together the resources and expertise of both PEPFAR and the Global Fund

Related Questions

How will the partnership with PEPFAR and the anticipated rollout of lenacapavir affect Gilead's revenue forecasts and stock valuation? What is the competitive landscape for HIV PrEP injectables in low- and lower‑middle‑income markets, and how does lenacapavir compare to existing products like cabotegravir? What are the potential risks and timelines related to regulatory approvals, manufacturing scale‑up, and pricing negotiations that could influence the long‑term performance of Gilead's HIV prevention portfolio?
Find similar articles on Candlesense businesswire